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Amyloid fibril formation and protein misassembly: a structural
quest for insights into amyloid and prion diseases
Jeffery W Kelly
The assembly and misassembly of normally soluble
proteins into fibrilar structures is thought to be a causative
agent in a variety of human amyloid and prion diseases.
Structural and mechanistic studies of this process are
beginning to elucidate the conformational changes
required for the conversion of a normally soluble and
functional protein into a defined quaternary structure.
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Protein assembly and misassembly processes are difficult
to characterize by conventional X-ray crystallography and
multidimensional solution NMR studies owing to the non-
crystallinity and the insolubility of the fibrilar form of the
assembled protein [1,2]. However, these methods have a
very important role to play in characterizing both the struc-
ture of the native fold of the precursor protein and the ter-
tiary structure(s) of the intermediate(s) that render a given
protein capable of self-assembly into an amyloid fibril.
Moreover, by creatively modifying the precursor protein it
is possible to arrest the assembly process at an intermedi-
ate stage such that an X-ray structure of an assembly inter-
mediate can be determined [3–5]. The fibrilar structure
resulting from the assembly of an alternative conformation
of any one of the 16 normally soluble and functional
human amyloidogenic proteins is thought to be the
causative agent in a variety of human amyloid and prion
diseases [6–17]. Support for the prion hypothesis comes
from research on yeast where the self-assembly of the N-
terminal domain of Sup35 is responsible for the dominant
cytoplasmically inherited [PSI+] phenotypic trait [18].
[PSI+] cells have the ability to read through the nonsense
codons present in certain genes, resulting in the synthesis
of novel proteins [19,20]. As Sup35 is a subunit of the
translation release factor that allows ribosomes to terminate
translation at nonsense codons, it has been argued that the
[PSI+] phenotype is simply another mechanism for yeast to
adapt to stressful environments by producing a new subset
of proteins. It will be very interesting to see how many
examples there are of intracellular proteins which self-
assemble and provide genetic variation to a cell.
There are two basic types of protein self-assembly
mechanisms. Assembly can occur from a conformational
intermediate produced during folding or denaturation, as
is the case for inclusion body formation and amyloid fibril
formation (Fig. 1), respectively [6,21,22]. Alternatively,
the native three-dimensional structure of a protein can
become susceptible to self-assembly through surface
mutations, as in the case of Sickle cell hemoglobin, or due
to a change in environment analogous to the conditions
facilitating protein crystallization [23]. X-ray crystallogra-
phy is easily applied in understanding the latter case,
where the normal tertiary structure facilitates self-assem-
bly through quaternary contacts, but does not apply
directly to characterizing the intermediate structure(s) in
the former case. In this minireview we use the terms
assembly and misassembly to characterize ordered quater-
nary structure formation and reserve the term aggregation
for those cases where a protein forms a non-regular amor-
phous oligomeric structure.
Amyloid fibril formation refers to an in vivo self-assembly
process where any one of 16 normally soluble and func-
tional human proteins are transformed into an insoluble,
cross-b fibrilar quaternary structure. The fibrils derived
from different precursor proteins have similar structural
features, despite only modest primary and tertiary
structural homology amongst the precursor proteins
[1,6,7,24,25]. The low structural homology is reflected in
the apparently unrelated functions of the amyloidogenic
proteins in vivo. For example, transthyretin (TTR) trans-
ports thyroxine and the retinol-binding protein in the
cerebral spinal fluid and in the blood, whereas lysozyme is
an enzyme that destroys bacterial cell walls. Biophysical
studies on TTR [26–32] and variants thereof [33,34],
immunoglobulin light chains [12], and more recently
lysozyme [11], highlight the requirement of conforma-
tional changes for the conversion of these proteins into
amyloid fibrils [6,8]. Under partially denaturing condi-
tions, amyloidogenic proteins appear to be able to adopt
alternative conformations which render these proteins
capable of self-assembly into amyloid fibrils [6]. The
observation that apparently unrelated proteins can form
amyloid having a common tertiary and quaternary struc-
ture can be rationalized by considering the possibility that
a portion of the structure formed under partially denatur-
ing conditions is a common core b sheet that allows this
subset of proteins to assemble into the amyloid quaternary
structure. The amorphous regions of amyloid derived from
different proteins are likely to vary, however, not much
information is available on the amorphous regions at this
time. The mechanism governing the assembly of the amy-
loidogenic intermediate into amyloid is rather complex
and involves several discernible quaternary structural
intermediates (see references [6,35–40]).
To outline what can be achieved with respect to a struc-
tural understanding of protein assembly, the next section
focuses on our current understanding of TTR amyloid
fibril formation. Our present knowledge of this process
was obtained employing a combination of biophysical and
structural methods. It can be argued that TTR and its
associated amyloid diseases are better understood than
any other human amyloid disease [6,7,27,32,41–48]. In
unfortunate individuals wild-type TTR is converted into
amyloid which appears to cause senile systemic amyloido-
sis (SSA). The age of onset is about 80 and the disease is
sometimes characterized by heavy amyloid deposits in the
heart leading to congestive heart failure [49,50]. Familial
amyloid polyneuropathy (FAP) occurs much earlier in life
than the senile form of the disease, onset being as early as
the second decade of life in the case of one variant
(Leu55→Pro) [45,51–53]. FAP patients are predominantly
heterozygous individuals having one of over 50 single site
variants of TTR in their systemic amyloid deposits. All of
the early onset TTR amyloid disease cases observed to
date are associated with a mutation in TTR, implying that
the mutation makes the protein more amyloidogenic. The
majority of the FAP mutations are conservative surface
mutations and as such would not be expected to change
the overall three-dimensional structure of TTR [54].
The structure of wild-type TTR was determined by Blake
and his colleagues at Oxford in the 1970s [55,56]. One pos-
sibility to explain the amyloidogenicity of the variant FAP
forms of TTR, relative to the wild-type, is that the muta-
tions simply allow the normally folded TTR tetramers to
undergo self-assembly, analogous to the sickle cell hemo-
globin situation. However, several experiments demon-
strate that TTR tetramers do not form amyloid, even
when the tetrameric FAP variants are incubated well
above physiological  concentrations. The X-ray crystal
structures of several of the FAP-associated TTR variants
have now been solved, including the most common
Val30→Met mutant. These variants exhibit structures
which are virtually identical to the structure of the wild-
type protein [57–60]. This is not surprising, given the con-
servative nature of the majority of these mutations [54].
If the mutations do not affect the normally folded struc-
ture then they are likely to perturb either the thermody-
namics and/or the kinetics of the folding/denaturation
pathway [6,8,10,11,61,62]. Wild-type TTR will form
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Figure 1
Outline of the role that conformational
changes play in the conversion of a normally
soluble and functional protein into amyloid.
Amyloidogenic proteins appear to adopt
alternative conformations which have common
structural features.
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amyloid in vitro when subjected to partial acid denatura-
tion conditions (within the pH range 5.1–3.9) and during
pH-mediated reconstitution from an unfolded state
(pH 3.9–5.8). These observation suggest that an interme-
diate of the denaturation/ reconstitution pathway par-
titions into amyloid at physiological TTR concentrations
(0.2–0.3 mgml–1) and temperature (37°C) [26,27,29–34].
The FAP TTR variants make more amyloid than the wild
type and exhibit fibril formation within a higher pH range,
strongly suggesting that the mutations do indeed alter the
denaturation pathway [27,29,33,34]. The fact that these
mutations allow amyloid to form over a higher pH range is
physiologically important, because protein turnover nor-
mally takes place at pH 5.5 [6,33,34,63]. If fibril formation
is efficient under normal protein turnover conditions,
affected individuals should develop amyloid disease much
earlier in life due to the large mass of amyloid accumu-
lated. The tertiary and quaternary structure of the TTR
intermediate(s) that lead to amyloid fibril formation have
been identified by unlinking denaturation and fibril for-
mation [29]. Analytical ultracentrifugation studies are the
principal method used for evaluating quaternary structural
changes as a function of pH, whereas spectroscopic
methods (such as near and far UV circular dichroism and
fluorescence spectroscopy in combination with single
tryptophan containing variants) facilitate characterization
of the pH-dependent tertiary structural changes
[27,29–31]. These methods lead us to the denaturation
pathway shown in Figure 2. The data accumulated
suggest that TTR must dissociate into monomeric form
and undergo a tertiary structural change in order to be
competent to self-assemble into amyloid [6].
Only very recently have conditions been identified which
allow TTR to be stabilized in its monomeric amyloidogenic
intermediate conformation for possible multidimensional
NMR evaluation. Dobson, Wuthrich, Dyson, Wright,
Baum, and others have clearly demonstrated that, while
difficult, NMR structure determination on intermediates of
this type is feasible and provides a wealth of information
[64–66]. By N-methylating critical hydrogen-bonding
residues or through equivalent modifications, it is possible
to block self-assembly at an early oligomer stage, prevent-
ing the formation of fibrils and making the structure
amenable to crystallographic structure determination [3].
From emerging studies employing atomic force micro-
scopy, electron microscopy, and analytical ultracentrifuga-
tion methods it is now apparent that fibril quaternary
structures are quite complex [35–39]. These techniques
have been used to observe multiple quaternary structural
intermediates prior to the formation of amyloid fibrils.
Because quaternary structural interactions are very impor-
tant in fibril formation, caution must be exercised when
evaluating an assembly terminated amyloid structure,
such as a dimeric structure. Such a structure may lack the
quaternary interactions that are characteristic of the true
amyloid structure. These results also force one to consider
the possibility that one or more of these soluble quater-
nary structural intermediates may play a key role in the
etiology of amyloid disease [6,32]. Undoubtedly, methods
will be discovered (for example those utilizing small mol-
ecule inhibitors) that block the conversion of one quater-
nary structure into the next, allowing us to unlink the
assembly equilibria characteristic of amyloid formation.
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Figure 2
The pH-dependent denaturation/amyloid fibril
formation pathway exhibited by transthyretin
(TTR).
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The key to the structural characterization of amyloid
fibrils by X-ray diffraction analysis is predicated on orient-
ing the fibrils [2]. Blake and his colleagues at Oxford were
able to isolate oriented Val30→Met TTR fibrils from the
vitreous humour of a homozygous FAP patient. These
fibrils were studied employing a synchrotron radiation
source using partially dried samples mounted on a stretch
frame. A high angle diffraction pattern was observed
showing meridional reflections out to 2Å resolution [2].
This pattern is consistent with a novel cross-b helical
structure, having 24 b strands per turn of the b helix
which extends indefinitely in the helical axis direction. It
appears that the b-helical protofilament is four twisted b-
helices thick (50–60 Å in diameter), although the orienta-
tion of the individual b strands cannot be discerned from
the data. Four b-helical protofilaments further associate to
form a fibril, as discerned from the cross-sectional views
observed in electron microscopy studies (130Å in diame-
ter) [2,67]. Consistent with the X-ray diffraction data, the
proposed structural model of amyloid requires a consider-
able tertiary structural rearrangement; this is in agreement
with the rearrangement suggested by independent bio-
physical data and V8 proteolysis sensitivity data [6].
Although the proposed b-helical structure of TTR
amyloid is consistent with a number of observations, it is
based on a small number of wide-angle reflections, as
pointed out by Kirschner. As such, further experiments
are needed to provide more experimental evidence for the
b-helical structural model of amyloid [68].
In summary, structural information on the precursor 
proteins, the structurally altered monomeric intermedi-
ates, the quaternary structural assembly intermediates,
and the amyloid fibrils themselves will be very useful for
improving our understanding of protein assembly and mis-
assembly in general and specifically in the case of amyloid
fibril formation.
Recent examples of the application of structural methods
to study protein assembly include Wuthrich’s structure of
the PrP 121–231 domain of the prion precursor protein.
This structure contains the residues that are changed in
nine of the familial prion diseases as well as two glycosyla-
tion sites and the disulfide bond [69]. The PrP domain
structure should represent the normal structure of the
prion protein, however, one needs to realize that neither
glycosylation site is post-translationally modified, which
could change the structure of the precursor protein. The
crystal structures of the native folds of both of the amy-
loidogenic variants of lysozyme have recently been
reported. These structures show changes in the critical
interface between the a and b domains, as compared to the
wild-type protein, which could enhance their amyloido-
genicity. In addition, the UK group headed by Pepys has
used a number of biophysical methods to show that an
intermediate molten globule state is the lysozyme interme-
diate that leads to amyloid fibril formation [11]. Studies on
the time course of Alzheimer’s fibril formation by the
Krafft and Lansbury groups, have shown that before the
mature fibrils appear in vitro at least two quaternary struc-
tural intermediates accumulate during Alzheimer’s b-
amyloid fibril formation [39,40]. Studies such as these will
continue to increase our understanding of protein self-
assembly. The Lansbury and Griffin laboratories as well as
the Kirschner laboratory have proposed structural models
for the Alzheimer’s b-amyloid using solid state NMR and
X-ray diffraction methods, respectively [70,71]. Continuing
efforts from these and other laboratories should result in a
high-resolution model for the Alzheimer’s amyloid fibril.
The role of structural methods in developing therapeutic
strategies for intervention in amyloid disease is particu-
larly attractive [72]. The mechanism of TTR denatura-
tion, depicted in Figure 2, suggests that amyloid fibril
formation could be inhibited in two ways: by preventing
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Figure 3
Ligand binding stabilizes the normal fold of
the amyloidogenic protein transthyretin (TTR),
thus preventing the formation of the alternative
conformation which leads to amyloid fibril
formation.
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the conformational changes leading to the formation of the
amyloidogenic intermediate or by interfering with the
process of assembly [6,72] (Fig. 3). Preventing the confor-
mational changes has proven to be straightforward using
molecules like 2,4,6-triiodophenol which bind with high
affinity to TTR [72,73]. Ligand binding stabilizes the
tetramer against the conformational changes that lead to
amyloid fibril formation at pH 4–5.5 [72]. A recent struc-
ture-based design approach has led to the production of a
number of very interesting compounds which inhibit
TTR fibril formation in vitro. Two of these compounds
have the appropriate pharmacodynamics to warrant evalu-
ation in FAP patients (SA Peterson, T Klabunde, H
Lashuel, JC Sacchettini and JWK, unpublished data).
These new approaches towards the treatment of condi-
tions such as FAP hold much promise for the treatment of
amyloid diseases in the future.
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